MiR-101 And Coxorubicin Co-delivered By Liposomes Suppressing Malignant Properties Of Hepatocellular Cancinoma

Background & Aim : Mi R-101 is an important tumor-suppressive micro RNA(miRNA)in hepatocellular carcinoma(HCC)and can increase the sensitivity of chemotherapeutic drugs.However,miR-101 based combination therapies with doxorubicin(DOX)are not reported yet.Recently,nanomaterials,especially liposome formulations have been approved for clinical use and provide a great opportunity to co-deliver therapeutic agents for cancer therapy.The aim of the present study was to evaluate the better combinative therapy effect of miR-101/doxorubicin liposome(miR-101/DOX-L)than medication alone in HCC.Methods:The anti-tumor effects of miR-101/DOX-L on HCC in vitro were evaluated through analyzing cell proliferation,colony formation,cell migration,cell invasion,cell apoptosis assay and the expression of related genes.In subcutaneous xenografts developed by HCC cells,the inhibition of tumor growth was analyzed through gross morphology,growth curve,proliferation marker Ki-67,apoptosis signals and the expression of related molecules.Results:Liposome(L)nanoparticles were successfully prepared and could efficiently deliver miR-101 and DOX to HCC cells simultaneously.Mi R-101/DOX-L exhibits significantly synergistical anti-tumor effects to HCC cells in vitro and in vivo by working on miR-101's target genes and DOX's effective molecules.Conclusions:Our results indicated that liposome nanoparticle is a reliable delivery strategy to co-deliver miR-101 and DOX simultaneously,and miR-101/DOX-L would be developed as a promising therapeutic candidate for unresectable HCC.